» Articles » PMID: 8213351

Interleukin-1 (IL-1) Production in a Mouse Tissue Chamber Model of Inflammation. I. Development and Initial Characterisation of the Model

Overview
Journal Agents Actions
Specialty Pharmacology
Date 1993 Mar 1
PMID 8213351
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

A simple and reliable animal model to quantify interleukin-1 (IL-1) production at a site of inflammation has been developed and characterised. This model involves the subcutaneous implantation of sterile Teflon chambers (30 mm x 10 mm diameter) into the backs of mice. After 14 days, a straw coloured transudate fluid was present in the lumen of the implanted chamber which was withdrawn for the determination of baseline measurements of various inflammatory parameters. A localised chronic inflammatory response was then induced in the chambers by injection of 1% zymosan or Bordetella pertussis vaccine (BPV) (in presensitised animals). The local inflammatory reaction in the chamber, over a 30 day time course, was characterised by leucocyte infiltration, and marked increases in protein, prostaglandin E2, IL-1 and IL-6 concentrations in the chamber fluid. A rapid increase in plasma concentrations of the acute-phase reactant serum amyloid P (SAP) also occurred. This model allows repeated samples to be obtained from the same animal for the assessment of inflammatory parameters and may be useful for investigating the mechanisms controlling the production of IL-1 during the inflammatory response in vivo.

Citing Articles

Secreted Gaussia princeps luciferase as a reporter of Escherichia coli replication in a mouse tissue cage model of infection.

Liu M, Blinn C, McLeod S, Wiseman J, Newman J, Fisher S PLoS One. 2014; 9(3):e90382.

PMID: 24595353 PMC: 3942414. DOI: 10.1371/journal.pone.0090382.


Silver coordination polymers for prevention of implant infection: thiol interaction, impact on respiratory chain enzymes, and hydroxyl radical induction.

Gordon O, Slenters T, Brunetto P, Villaruz A, Sturdevant D, Otto M Antimicrob Agents Chemother. 2010; 54(10):4208-18.

PMID: 20660682 PMC: 2944614. DOI: 10.1128/AAC.01830-09.


In vivo tumor secretion probing via ultrafiltration and tissue chamber: implication for anti-cancer drugs targeting secretome.

Huang C, Nakatsuji T, Liu Y, Shi Y Recent Pat Anticancer Drug Discov. 2008; 3(1):48-54.

PMID: 18289123 PMC: 2772193. DOI: 10.2174/157489208783478694.


In vivo survival of teicoplanin-resistant Staphylococcus aureus and fitness cost of teicoplanin resistance.

McCallum N, Karauzum H, Getzmann R, Bischoff M, Majcherczyk P, Berger-Bachi B Antimicrob Agents Chemother. 2006; 50(7):2352-60.

PMID: 16801412 PMC: 1489778. DOI: 10.1128/AAC.00073-06.


Tissue chambers--a useful model for in vivo studies of cytokine production in the pig.

Wattrang E, Wallgren P, Fuxler L, Lindersson M, Fossum C Vet Immunol Immunopathol. 1997; 56(1-2):133-50.

PMID: 9220587 PMC: 7119702. DOI: 10.1016/s0165-2427(96)05733-9.


References
1.
PILLEMER L, Blum L, Lepow I, Ross O, Todd E, Wardlaw A . The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science. 1954; 120(3112):279-85. DOI: 10.1126/science.120.3112.279. View

2.
Orencole S, Dinarello C . Characterization of a subclone (D10S) of the D10.G4.1 helper T-cell line which proliferates to attomolar concentrations of interleukin-1 in the absence of mitogens. Cytokine. 1989; 1(1):14-22. DOI: 10.1016/1043-4666(89)91044-2. View

3.
Ferreira S . Prostaglandins, aspirin-like drugs and analgesia. Nat New Biol. 1972; 240(102):200-3. DOI: 10.1038/newbio240200a0. View

4.
Zimmerli W, Zak O, Vosbeck K . Experimental hematogenous infection of subcutaneously implanted foreign bodies. Scand J Infect Dis. 1985; 17(3):303-10. DOI: 10.3109/inf.1985.17.issue-3.10. View

5.
Dieppe P, Willoughby D, Huskisson E, ARRIGONI-MARTELLI E . Pertussis vaccine pleurisy: a model of delayed hypersensitivity. Agents Actions. 1976; 6(5):618-21. DOI: 10.1007/BF01971580. View